Intervention

Sacituzumab Tirumotecan

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 10 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials10
Recruiting5
Common conditions16
Lead sponsors shown8
Advertisement

Clinical trials

10 shown
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT07329322 · 2026-03-30
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19
RECRUITING
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)NCT07179783 · 2025-09-22
RECRUITING
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22
RECRUITING
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972 · 2024-08-07
RECRUITING
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior ChemotherapyNCT07639086 · 2026-08-31
NOT_YET_RECRUITING
GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)NCT07738341 · 2026-08-01
NOT_YET_RECRUITING
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNCT07388875 · 2026-02-24
NOT_YET_RECRUITING
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNCT07193160 · 2025-11-01
NOT_YET_RECRUITING
Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBCNCT07007780 · 2025-08-20
NOT_YET_RECRUITING

Common conditions

Trial status mix

NOT_YET_RECRUITING5
RECRUITING5

Phase mix

PHASE28
PHASE12
PHASE32
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.